• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TEDEC-MEIJI FARMA GENVISC 850; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TEDEC-MEIJI FARMA GENVISC 850; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Model Number 50653-0006-01
Device Problem No Apparent Adverse Event (3189)
Patient Problems Pain (1994); Arthralgia (2355); Joint Swelling (2356)
Event Date 08/31/2016
Event Type  Injury  
Manufacturer Narrative
Suspect medical device, genvisc 850 sodium hyaluronate (ha) 10 mg/ml with a (b)(4), was manufactured, tested and released by (b)(4) according to fda approved processes and specifications.(b)(4), as part of the release of the product to the us market and additionally when evaluating this case, reviewed product components-release documentation (e.G.Bulk ha and syringe primary package, among others) as well as manufacturing batch records, product testing, and release documentation.In addition, as part the device design shipping study protocol, upon product arrival to the warehouse, in tennessee usa, genvisc 850 was retested for ha content and for sterility.Through out these series of evaluations, genvisc 850 complied with all the requirements of sterility, ha content as well as all the other specification required for release of the product to the us market.No findings were observed that would indicate that there is and issue with the suspect medical device in relation to product manufacturing process and release compliance.
 
Event Description
Clinic reported to ae assessor that pt.Had immediate swelling of knee with first genvisc 850 injection in the knee.Ae assessor spoke with the clinic operations supervisor for further investigation of this report.Pt.Presented to clinic on (b)(6) 2016 with bilateral knee pain, rated 6/10, with left > right and past medical history of left knee surgery in 1965 for a football injury.Clinic reports existing evidence of surgical scars and wires around the left patella.Bilateral genvisc 850 injections given on (b)(6) 2016 for diagnosis of knee pain and bilateral synovitis.Pt.Returned to the clinic on (b)(6) 2016 and the right knee was swollen; no redness or warmth noted.It was not documented in the chart that the swelling resulted immediately after the genvisc 850 injection.Right knee pain was rated 1/10 and 60 cc of clear yellow fluid was aspirated from the right knee with a toradol injection given into the right knee.On (b)(6) 2016 the pt.Returned to the clinic for follow-up and a right knee ultrasound showed moderate effusion; right knee aspirate done with 25 cc of clear yellow fluid aspirated - no pain indicated in the chart.On (b)(6) 2016 left knee genvisc 850 given for pain 1/10.Right knee pain and swelling resolved and pt.Only continued with genvisc 850 to the left knee.Pt.Had remaining left knee genvisc 850 injections on (b)(6) 2016; clinic noted the injections were tolerated well and pain at the end of the series was 0/10.Pt.Only remaining symptom at the end of the genvisc 850 series was left knee crepitus; right and left knee pain improved.Pt.Did develop right knee swelling/effusion x 2 after first genvisc 850 injection.Although pt.Had existing bilateral knee pathology, genvisc 850 injection cannot be excluded as a contributory factor to the swelling.The right knee swelling/ effusion resolved and there was no evidence of infection.This case will be closed without further follow-up from the ae assessor.The case will be closed as serious due to the reported effusion which required intervention.Based upon the information provided there is no remedial action required.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GENVISC 850
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
TEDEC-MEIJI FARMA
ctra. m-300, km 30, 500
alcala de henares (madrid), 28802
SP  28802
Manufacturer (Section G)
TEDEC-MEIJI FARMA
ctra. m-300, km 30,500
alcala de henares, madrid 28802
SP   28802
Manufacturer Contact
celia vazquez lopez
ctra. m-300, km 30, 500
alcala de henares, madrid 28802
SP   28802
18870980
MDR Report Key6231869
MDR Text Key64125200
Report Number3003184440-2017-00003
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier00850653006016
UDI-Public(01)00850653006016(17)180630(10)J1
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P140005
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type distributor
Reporter Occupation Physician
Type of Report Initial
Report Date 01/07/2017,10/25/2016
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/07/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date06/30/2018
Device Model Number50653-0006-01
Device Lot NumberJ1
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Date Report Sent to FDA01/07/2017
Distributor Facility Aware Date10/25/2016
Device Age1 HR
Event Location Home
Date Report to Manufacturer10/13/2016
Date Manufacturer Received10/25/2016
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/19/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age65 YR
-
-